Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solifenacin - Astellas Pharma

Next Previous
X
Search
Drug Profile

Solifenacin - Astellas Pharma

Alternative Names: Bispec; Solifenacin succinate; Vesicare; VESIcare LS; Vesicare OD; VESIcare®; YM 67905; YM 905

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Class Esters; Irritable bowel syndrome therapies; Isoquinolines; Quinuclidines; Small molecules; Urologics
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • No development reported Irritable bowel syndrome

Most Recent Events

  • 26 Dec 2022 Solifenacin is still in registration for Overactive bladder (In adolescents, In children) in USA (Astellas pipeline, December 2022)
  • 27 May 2020 Astellas Pharma plans to launch solifenacin succinate (VESIcare LS™) for Overactive bladder in USA (PO) in late 2020
  • 26 May 2020 Efficacy data from a phase III clinical trial in Overactive bladder in paediatric patients released by Astellas Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top